| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Clinical Sciences of Companion Animals (JK, GRR, ET) and Pathology (MK), Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
Histologic grade is an important determinant in clinical outcome of human osteosarcoma (OS). In this study, the histologic characteristics of primary and metastatic canine OS were evaluated using a new classification system. Histologic characteristics were classified in 166 primary and 34 metastatic canine OS. Prognostic variables for clinical outcome were determined using multivariate analysis. Most OS were histologically characterized by severe to extreme cellular pleomorphism, a variable number of mitoses, small to moderate amounts of matrix, a high percentage of tumor cells, and minimal to moderate amounts of necrosis. Tumor invasion into vessels was present in 117/152 (71%) tumors, and 12/50 (24%) of the regional lymph nodes had evidence of metastasis. Classification of the 166 tumors resulted in seven (4%) grade I, 34 (21%) grade II, and 125 (75%) grade III OS. In the multivariate analysis, histologic grade III OS and elevated pretreatment plasma alkaline phosphatase (AP) levels were independent predictors of clinical outcome. Dogs with high-grade tumors and elevated AP should be carefully evaluated for the presence of metastatic disease before starting adjunctive therapy protocols.
Key words: Dogs; grading system; osteosarcoma; prognosis.
Request reprints from Dr. J. Kirpensteijn, Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, PO Box 80.154, 3508 TD Utrecht (The Netherlands).
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:
![]() |
B. Phillips, B. E. Powers, W. S. Dernell, R. C. Straw, C. Khanna, G. S. Hogge, and D. M. Vail Use of Single-Agent Carboplatin as Adjuvant or Neoadjuvant Therapy in Conjunction With Amputation for Appendicular Osteosarcoma in Dogs J. Am. Anim. Hosp. Assoc., January 1, 2009; 45(1): 33 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Chun, L. D. Garrett, C. Henry, M. Wall, A. Smith, and N. M. Azene Toxicity and Efficacy of Cisplatin and Doxorubicin Combination Chemotherapy for the Treatment of Canine Osteosarcoma J. Am. Anim. Hosp. Assoc., November 1, 2005; 41(6): 382 - 387. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Liptak, W. S. Dernell, R. C. Straw, S. A. Rizzo, M. H. Lafferty, and S. J. Withrow Proximal Radial and Distal Humeral Osteosarcoma in 12 Dogs J. Am. Anim. Hosp. Assoc., November 1, 2004; 40(6): 461 - 467. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Hoenerhoff, M. Kiupel, D. Rosenstein, and R. R. Pool Multipotential Osteosarcoma with Various Mesenchymal Differentiations in a Young Dog Vet. Pathol., May 1, 2004; 41(3): 264 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Loukopoulos, B. A. Mungall, R. C. Straw, J. R. Thornton, and W. F. Robinson Matrix Metalloproteinase-2 and -9 Involvement in Canine Tumors Vet. Pathol., July 1, 2003; 40(4): 382 - 394. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |